57,551 results match your criteria inhibitors angiotensin

Current pharmacological management of aortic aneurysm.

J Cardiovasc Pharmacol 2021 May 10. Epub 2021 May 10.

Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 200032, China.

Abstract: Aortic aneurysm (AA) remains one of the primary causes of death worldwide. Of the major treatments, prophylactic operative repair is used for AA to avoid potential aortic dissection (AD) or rupture. To halt the development of AA and alleviate its progression into AD, pharmacological treatment has been investigated for years. Read More

View Article and Full-Text PDF

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.

Neurotherapeutics 2021 May 13. Epub 2021 May 13.

Institute for Systems Analysis and Computer Science "A. Ruberti", National Research Council (IASI-CNR), Via Dei Taurini 19, 00185, Rome, Italy.

The continuous adherence to the conventional "one target, one drug" paradigm has failed so far to provide effective therapeutic solutions for heterogeneous and multifactorial diseases as amyotrophic lateral sclerosis (ALS), a rare progressive and chronic, debilitating neurological disease for which no cure is available. The present study is aimed at finding innovative solutions and paradigms for therapy in ALS pathogenesis, by exploiting new insights from Network Medicine and drug repurposing strategies. To identify new drug-ALS disease associations, we exploited SAveRUNNER, a recently developed network-based algorithm for drug repurposing, which quantifies the proximity of disease-associated genes to drug targets in the human interactome. Read More

View Article and Full-Text PDF

A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.

Ann Transl Med 2021 Apr;9(8):716

Steno Diabetes Center Copenhagen, Denmark.

Diabetic kidney disease is a frequent and costly complication to type 2 diabetes. After many years with a lack of successful trials there are now significant developments that will change treatment, guidelines and future outcome. Since the last two decades blockade of the renin-angiotensin system (RAS) is standard treatment, but new antidiabetic treatments have shown potential for kidney protection. Read More

View Article and Full-Text PDF

Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities.

Front Pharmacol 2021 27;12:646076. Epub 2021 Apr 27.

Institute for Health and Equity, Division of Biostatistics, Medical College of WI, Milwaukee, WI, United States.

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain injuries in rodent models and may mitigate delayed radiation injuries after radiotherapy. Rat models of partial body irradiation sparing part of one hind leg (leg-out PBI) have been developed to simultaneously expose multiple organs to high doses of ionizing radiation and avoid lethal hematological toxicity to study the late effects of radiation. Read More

View Article and Full-Text PDF

Mechanisms and Models in Heart Failure: A Translational Approach.

Circ Res 2021 May 13;128(10):1435-1450. Epub 2021 May 13.

Duke Clinical Research Institute and Duke University School of Medicine, Durham, Duke University, NC (G.M.F.).

Despite multiple attempts to develop a unifying hypothesis that explains the pathophysiology of heart failure with a reduced ejection fraction (HFrEF), no single conceptual model has withstood the test of time. In the present review, we discuss how the results of recent successful phase III clinical development programs in HFrEF are built upon existing conceptual models for drug development. We will also discuss where recent successes in clinical trials do not fit existing models to identify areas where further refinement of current paradigms may be needed. Read More

View Article and Full-Text PDF

Timely and individualized heart failure management: need for implementation into the new guidelines.

Clin Res Cardiol 2021 May 13. Epub 2021 May 13.

Klinik Für Innere Medizin III-Kardiologie, Angiologie Und Internistische Intensivmedizin, Universitätsklinikum Des Saarlandes, Kirrberger Strasse 100, 66421, Homburg, Germany.

Due to remarkable improvements in heart failure (HF) management over the last 30 years, a significant reduction in mortality and hospitalization rates in HF patients with reduced ejection fraction (HFrEF) has been observed. Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve outcomes for patients with HFrEF to reduce mortality and HF hospitalization. This includes established device therapies, such as implantable defibrillators and cardiac resynchronization therapies, which improved patients' symptoms and prognosis. Read More

View Article and Full-Text PDF

Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor.

Khue Vu Nguyen

Nucleosides Nucleotides Nucleic Acids 2021 May 13:1-32. Epub 2021 May 13.

Department of Medicine, Biochemical Genetics and Metabolism, The Mitochondrial and Metabolic Disease Center, School of Medicine, University of California, San Diego, San Diego, CA, USA.

The outbreak of a novel coronavirus responsible for the severe acquired respiratory syndrome: SARS-CoV-2, also known as coronavirus disease 2019: COVID-19, represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for diagnostic, development of antibodies, entry inhibitors, and vaccines. COVID-19 also recognizes angiotensin-converting enzyme 2 (ACE2) as its host receptor binding to viral S protein. Read More

View Article and Full-Text PDF

Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.

Front Cardiovasc Med 2021 26;8:609857. Epub 2021 Apr 26.

Peking University People's Hospital, Beijing, China.

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) share a target receptor with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The use of ACEIs/ARBs may cause angiotensin-converting enzyme 2 receptor upregulation, facilitating the entry of SARS-CoV-2 into host cells. There is concern that the use of ACEIs/ARBs could increase the risks of severe COVID-19 and mortality. Read More

View Article and Full-Text PDF

A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19.

PeerJ 2021 23;9:e11171. Epub 2021 Apr 23.

NASI Senior Scientist Platinum Jubilee Fellow, Biotech Park, Lucknow, Uttar Pradesh, India.

Background & Objectives: The massive outbreak of Novel Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) has turned out to be a serious global health issue worldwide. Currently, no drugs or vaccines are available for the treatment of COVID-19. The current computational study was attempted to identify a novel therapeutic inhibitor against novel SARS-CoV-2 using in silico drug discovery pipeline. Read More

View Article and Full-Text PDF

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.

BMC Med 2021 05 12;19(1):118. Epub 2021 May 12.

Department of Cardiology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

Background: In the first wave of the COVID-19 pandemic, the hypothesis that angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) increased the risk and/or severity of the disease was widely spread. Consequently, in many hospitals, these drugs were discontinued as a "precautionary measure". We aimed to assess whether the in-hospital discontinuation of ARBs or ACEIs, in real-life conditions, was associated with a reduced risk of death as compared to their continuation and also to compare head-to-head the continuation of ARBs with the continuation of ACEIs. Read More

View Article and Full-Text PDF

Revised Korean Cough Guidelines, 2020: Recommendations and Summary statements.

Tuberc Respir Dis (Seoul) 2021 May 13. Epub 2021 May 13.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Cough is the most common respiratory symptom that can result from various causes, and is a major clinical problem that reduces patients' quality of life. Thus, clinical guidelines for the treatment of cough were established in 2014 by the cough guideline committee under the Korean Academy of Tuberculosis and Respiratory Diseases. From October 2018 to July 2020, the cough guidelines were revised by the members of the committee based on the first guidelines. Read More

View Article and Full-Text PDF

Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis.

Int J Artif Organs 2021 May 12:3913988211013366. Epub 2021 May 12.

Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital, Columbia University, New York, NY, USA.

Introduction: Gastrointestinal bleeding (GIB) remains a common and vexing complication of left ventricular assist device (LVAD) support. Recent single-center analyses suggest that ACE inhibitors (ACEi)/angiotensin receptor blockers (ARB) and digoxin may prevent GIB in LVAD patients. Here we evaluate the effect of guideline-directed medical therapies (GDMT) for heart failure (HF) on rates of GIB through analysis of the INTERMACS registry database. Read More

View Article and Full-Text PDF

An update on emerging therapeutics to combat COVID-19.

Basic Clin Pharmacol Toxicol 2021 May 11. Epub 2021 May 11.

Division of Veterinary Parasitology, Faculty of Veterinary Sciences and Animal Husbandry, Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu, R.S Pura-181102, J & K, India.

Background: The COVID-19 pandemic has demanded effective therapeutic protocol from researchers and clinicians across the world. Currently, a large amount of primary data have been generated from several preclinical studies. At least 300 clinical trials are underway for drug repurposing against COVID-19; the clinician needs objective evidence-based medication to treat COVID-19. Read More

View Article and Full-Text PDF

COVID-19 in Patients with Hypertension.

Adv Exp Med Biol 2021 ;1318:243-261

Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Baltimore, MD, USA.

Hypertension has been listed in several case series and retrospective cohorts as a potential risk factor for the incidence and severity of the new coronavirus (SARS-CoV-2)-associated disease (COVID-19). The debate is noteworthy because almost one billion people around the globe are estimated to have hypertensive diseases, according to the Global Burden of Disease study. Considering the SARS-CoV-2's high infectivity rates, a possible interaction between COVID-19 and hypertension is worrisome. Read More

View Article and Full-Text PDF

Oroesophageal Pemphigus vulgaris Secondary to Lisinopril Use: A New Side Effect.

Cureus 2021 Apr 6;13(4):e14333. Epub 2021 Apr 6.

Gastroenterology, Allegheny Health Network, Pittsburgh, USA.

Pemphigoid diseases are a group of blistering autoimmune pathologies including pemphigus vulgaris (PV) and pemphigus foliaceous, which affect mucocutaneous tissues. Non-steroidal anti-inflammatory drugs, penicillamine, and angiotensin-converting enzyme inhibitors such as captopril and enalapril are associated with drug-induced pemphigoid. We present a case of lisinopril-associated PV which has not been previously reported. Read More

View Article and Full-Text PDF

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.

Pathog Immun 2021 26;6(1):55-74. Epub 2021 Apr 26.

Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.

Background: Host proteases have been suggested to be crucial for dissemination of MERS, SARS-CoV, and SARS-CoV-2 coronaviruses, but the relative contribution of membrane versus intracellular proteases remains controversial. Transmembrane serine protease 2 (TMPRSS2) is regarded as one of the main proteases implicated in the coronavirus S protein priming, an important step for binding of the S protein to the angiotensin-converting enzyme 2 (ACE2) receptor before cell entry.

Methods: We developed a cell-based assay to identify TMPRSS2 inhibitors. Read More

View Article and Full-Text PDF

Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery.

Front Pharmacol 2021 23;12:662301. Epub 2021 Apr 23.

Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.

We investigated the respective effects of preoperative angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the incidence of postoperative acute kidney injury (AKI) and mortality. In this nested case-control study, we enrolled 20,276 patients who received major surgery. We collected their baseline demographic data, comorbidities and prescribed medication, the outcomes of postoperative AKI and mortality. Read More

View Article and Full-Text PDF

Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches.

J Mol Struct 2021 Sep 29;1240:130506. Epub 2021 Apr 29.

Pharmacology Division, CSIR-National Botanical Research Institute, Lucknow-226001, Uttar Pradesh, India.

The unprecedented quick spreading of newly emerged SARS-CoV-2, the virus responsible for causing COVID-19 has put the whole world in vast crisis. Several prophylactic interventions are being performed to discover the effective anti-COVID-19 agent. Thus, the present study aims to identify the cryptogamic secondary metabolites (CSMs) as potent inhibitors of two major targets of SARS-Cov2, namely 3-chymotrypsin-like protease (3CL) and receptor-binding domain (RBD) of spike glycoprotein (SGP), by implementing a computational approach. Read More

View Article and Full-Text PDF
September 2021

Predictors of adherence to composite therapy after acute coronary syndromes.

J Cardiovasc Med (Hagerstown) 2021 May 6. Epub 2021 May 6.

Division of Cardiology, Department of Advanced Biomedical Sciences, University of Napoli 'Federico II', Napoli, Italy.

Aims: Adherence to medical therapy following acute coronary syndrome (ACS) affects a patient's prognosis. In this cohort study, we sought to assess the factors that could affect a patient's adherence to therapy after ACS.

Methods: We prospectively collected information from patients (N = 964) hospitalized at the coronary care unit of the Federico II University Hospital, from 1 January 2015 to 30 June 2017, for ACS. Read More

View Article and Full-Text PDF

Intolerance to angiotensin converting enzyme inhibitors in asthma and the general population: a UK population-based cohort study.

J Allergy Clin Immunol Pract 2021 May 6. Epub 2021 May 6.

Division of Population Health and Genomics, University of Dundee, UK.

Background: Angiotensin converting enzyme inhibitor (ACEI) intolerance commonly occurs requiring switching to an angiotensin-II receptor blocker (ARB). ACEI intolerance may be mediated by bradykinin potentially affecting airway hyper-responsiveness.

Objective: Assess the risk of switching to ARBs in asthma. Read More

View Article and Full-Text PDF

Dyspnea With Unilateral Pulmonary Ground Glass Opacities and Cavitary Lesions.

Chest 2021 May;159(5):e337-e342

Section Pulmonary and Critical Care, St. Luke's University Health Network, Bethlehem, PA.

Case Presentation: A 62-year-old man presented with a 3-month history of shortness of breath and a dry cough. He had a medical history of hypertension (without use of angiotensin-converting enzyme inhibitors), hyperlipidemia, depression, and 10-pack-years of cigarette smoking several decades ago. He was a limousine driver and denied any history of occupational high-risk exposures. Read More

View Article and Full-Text PDF

Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.

Br J Clin Pharmacol 2021 May 7. Epub 2021 May 7.

College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109.

Background And Objective: Enalapril is a prodrug and needs to be activated by carboxylesterase 1 (CES1). A previous in vitro study demonstrated the CES1 genetic variant, G143E (rs71647871), significantly impaired enalapril activation. Two previous clinical studies examined the impact of G143E on single-dose enalapril PK (10 mg); however, the results were inconclusive. Read More

View Article and Full-Text PDF

Quality of care and risk of incident atrial fibrillation in patients with newly-diagnosed heart failure: A nationwide cohort study.

Eur Heart J Qual Care Clin Outcomes 2021 May 7. Epub 2021 May 7.

Danish Center for Clinical Health Services Research, Aalborg University, Aalborg, Denmark.

Aims: Incident atrial fibrillation (AF) is an adverse prognostic indicator in heart failure (HF); identifying modifiable targets may be relevant to reduce the incidence and morbidity of AF. Therefore, we examined the association between quality of HF care and risk of AF.

Methods And Results: Using the Danish Heart Failure Registry, we conducted a nationwide registry-based cohort study of all incident HF patients diagnosed between 2008 and 2018 and without history of AF. Read More

View Article and Full-Text PDF

Biomarkers of the severity of honeybee sting reactions and the severity and threshold of systemic adverse events during immunotherapy.

J Allergy Clin Immunol Pract 2021 May 4. Epub 2021 May 4.

University Hospital of Respiratory and Allergic Diseases, Golnik, Slovenia. Electronic address:

Background: A biomarker that could identify individuals at high risk for severe honeybee sting allergic reaction and/or systemic adverse events (SAEs) during venom immunotherapy (VIT) would improve the management of patients with honeybee (HB) venom allergy.

Objective: To identify biomarkers for risk of severe sting reactions or SAEs during VIT.

Methods: We recruited 332 patients undergoing honeybee VIT. Read More

View Article and Full-Text PDF

The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19.

Front Pharmacol 2021 20;12:667254. Epub 2021 Apr 20.

Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.

The renin-angiotensin-aldosterone system (RAAS) firstly considered as a cardiovascular circulating hormonal system, it is now accepted as a local tissue system that works synergistically or independently with the circulating one. Evidence states that tissue RAAS locally generates mediators with regulatory homeostatic functions, thus contributing, at some extent, to organ dysfunction or disease. Specifically, RAAS can be divided into the traditional RAAS pathway (or classic RAAS) mediated by angiotensin II (AII), and the non-classic RAAS pathway mediated by angiotensin 1-7. Read More

View Article and Full-Text PDF

Effect of medical treatment on heart failure incidence in patients with a systemic right ventricle.

Heart 2021 May 6. Epub 2021 May 6.

Adult Congenital Heart Centre, National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK.

Background: To date, clinical trials have been underpowered to demonstrate a benefit from ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in preventing systemic right ventricle (sRV) failure and disease progression in patients with transposition of the great arteries (TGA). This observational study aimed to estimate the effect of ACEi and ARB on heart failure (HF) incidence and mortality in a large population of patients with an sRV.

Methods: Data on all patients with an sRV under active follow-up at two tertiary centres between January 2007 and September 2018 were studied. Read More

View Article and Full-Text PDF

The Effect of Amiloride on Proteinuria in Patients with Proteinuric Kidney Disease.

Am J Nephrol 2021 May 6:1-10. Epub 2021 May 6.

Division of Nephrology and Hypertension, Department of Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.

Introduction: Proteinuric kidney diseases share an aggressive clinical course of developing end-stage renal disease. However, the treatment is limited. Amiloride, an epithelial sodium channel (ENaC) inhibitor, was reported to reduce proteinuria in animal studies and case reports independent of ENaC inhibition. Read More

View Article and Full-Text PDF

Heart failure management; a perspective from diabetes care.

Diabetes Res Clin Pract 2021 May 3:108849. Epub 2021 May 3.

Newcastle University, Newcastle upon Tyne, UK.

People with type 2 diabetes (T2DM) are recognized as having a 2-4 times increased risk of heart failure (HF). Ambulatory diabetes care has long concentrated on the prevention of microvascular and arterial disease, and surveillance for manageable problems such as with the feet and retinae. Accordingly, management of heart failure has never been a specific focus, although the preventative management of cardiac and kidney disease through glucose-lowering, blood pressure (BP) control, and blood lipid control have had a positive impact on its incidence. Read More

View Article and Full-Text PDF

The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.

Clin Exp Hypertens 2021 May 6:1-10. Epub 2021 May 6.

Department of Cardiology, University of Health Sciences Diyarbakır Gazi Yaşargil Education and Research Hospital, Diyarbakır, Turkey.

Introduction: We have aimed to investigate the relationship between use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin-receptor-blocker (ARB) drugs and acute hypoxemic respiratory failure (AHRF) and in-hospital mortality in hypertensive Covid-19 patients.

Material And Method: Consecutive 1345 patients diagnosed with Covid-19 between April and October 2020 who met inclusion criteria were divided into two groups based on presence and absence of AHRF and mortality. The groups were compared regarding epidemiological, clinical, radiological, laboratory findings and treatments methods. Read More

View Article and Full-Text PDF

Cardiac medication use in patients with suspected ischaemia without obstructive coronary arteries: sex differences and psychological distress.

Neth Heart J 2021 May 5. Epub 2021 May 5.

Department of Medical and Clinical Psychology, Centre of Research on Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands.

Background: Ischaemia without obstructive coronary arteries (INOCA) is more prevalent in women and associated with psychological distress. Pharmacological treatment goals are angina relief and cardiovascular risk management. The present study aims to examine sex differences in cardiac and non-cardiac medication use, as well as medication and sex differences related to consistent psychological distress in patients with suspected INOCA. Read More

View Article and Full-Text PDF